Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

NCT03292848 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

ADHD
Autism
Bipolar I Disorder
Conduct Disorder
Oppositional Defiant Disorder

Interventions

DRUG: Brexpiprazole

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborators

[object Object]